文献速递免疫规划卫生政策与健康促进

为疫苗政策提供信息的临床终点:儿童流感疫苗效力试验结局指标的系统综述

Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials.
PubMed 文献 · Vaccine · 2022-06-16

该系统综述纳入41项儿童流感疫苗随机对照试验,发现主要结局指标和采样标准高度变异,40种主要结局中仅1项定义更严重疾病但病例主要依据高体温。21项研究来自至少一个中低收入国家,其中15项(71%)于2010年后发表。多数中低收入国家无流感疫苗接种规划,该研究提示数据局限性可能影响政策和实施决策。

要点

  • 41项儿童流感疫苗效力试验中报告了40种不同的主要结局指标。
  • 33项研究(80%)报告了定义主要结局或触发采样的标准化症状或发现。
  • 仅1项研究定义了更严重疾病的主要结局,但病例主要基于高体温。

核心结论

  • 儿童流感疫苗效力试验的主要结局指标和临床采样标准高度变异,除1项例外均聚焦于捕获任何流感疾病。
  • 多数中低收入国家无流感疫苗接种规划,该研究提示数据局限性可能影响这些环境的政策和实施决策。

研究设计与样本

  • 系统综述,系统检索1980年以来≤18岁儿童、实验室确诊流感结局的3期或4期流感疫苗随机对照试验。
  • 从6455篇可能相关文献中纳入41项符合标准的研究。

主要发现

  • 21项研究(51%)在至少一个中低收入国家开展,其余研究(49%)仅在高收入国家开展。
  • 31项研究(76%)纳入6岁以下儿童。
  • 41项符合标准的研究中报告了40种不同的主要结局指标。
  • 33项研究(80%)报告了定义主要结局或触发标本采集的标准化症状或发现。
  • 1项研究定义了捕获更严重疾病的主要结局,但病例主要因高体温而无其他严重性标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We conducted a systematic review of pediatric influenza vaccine efficacy trials to assess clinical outcome measures and whether the trials defined important public health endpoints. MATERIAL AND METHODS: We systematically identified phase 3 or 4 influenza vaccine randomized controlled trials among children ≤18 years of age with laboratory-confirmed influenza outcomes since 1980. We recorded countries, age groups, vaccine formulations, specimen collection criteria, laboratory diagnostics, primary and secondary outcome measures, and funders, and we determined income category for study countries. We used descriptive statistics to summarize study characteristics. We analyzed the studies overall and a subset of studies conducted in at least one low- and middle-income country (LMIC). RESULTS: From 6455 potentially relevant articles, we identified 41 eligible studies. Twenty-one studies (51%) were conducted in at least one LMIC, while the remaining studies (49%) were conducted in high-income countries only. Thirty-one studies (76%) included children younger than six years. We found 40 different primary outcome measures among the 41 eligible studies. Thirty-three studies (80%) reported standardized symptoms or findings which defined a primary outcome or triggered specimen collection. One study defined a primary outcome which captured more severe illness; however, cases were mostly due to high body temperature without other severity criteria. Of the 21 studies from at least one LMIC, 15 (71%) were published since 2010 and 17 (81%) enrolled children younger than six years. Eighteen (86%) studies from at least one LMIC reported standardized symptoms or findings which defined a primary outcome or triggered specimen collection. CONCLUSIONS: Among pediatric influenza vaccine efficacy trials, primary outcome measures and clinical specimen collection criteria were highly variable and, with one exception, focused on capturing any influenza illness. As most LMICs do not have influenza vaccination programs, our study highlights a potential data limitation affecting policy and implementation decisions in these settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Braunfeld JB, Carson HN, Williams SR, et al. Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials. Vaccine. 2022. PMID: 35717265. doi:10.1016/j.vaccine.2022.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。